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Abstract
Background: Human Cytomegalovirus (HCMV) continues to be an important cause of morbidity
and occasional mortality in immunocompromised patients. Polymerase chain reaction (PCR) is the
most sensitive and commonly used method for the assessment of HCMV infection in the
immunocompromised patients at risk from severe associated clinical manifestations. However,
there is little consistency in the qualitative PCR used for different regions of HCMV genome.
Therefore, the performance of three Qualitative PCR tests to detect HCMV genome in clinical
specimens from immunocompromised patients was evaluated. With pp65 antigenemia assay as the
"gold standard", nested PCR for morphological transforming region II (mtr II) and glycoprotein O
(gO) gene and uniplex PCR for UL 83 gene were applied on 92 consecutive clinical specimens
obtained from 74 immunocompromised patients with clinically suspected HCMV disease. Virus
isolation was attempted on 12 clinical specimens from six pp65 antigenemia positive patients. Based
on the pp 65 antigenemia results as "gold standard", the sensitivity, specificity, positive predictive
value and negative predictive value for each PCR was calculated.
Results:  The PCR targeting mtr II region showed a higher sensitivity (100%) and negative
predictive value (100%) than the other two PCRs in detecting HCMV DNA from clinical specimens
obtained from different immunocompromised patient population of Chennai region, India.
Conclusion: The results suggests that the optimal method of detection of HCMV DNA could be
achieved by PCR using primer sequences targeting mtr II region of genome of HCMV in Chennai
region, India.
Background
Human Cytomegalovirus (HCMV), a widespread Herpes
virus, usually produces asymptomatic infections in
immunocompetent hosts. Serious disease can occur in
immunocompromised individuals and in congenitally
infected newborns. Symptoms in these patients range
from a mild disease to life threatening multiorgan system
disease. Conventional methods for laboratory diagnosis
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of CMV infection include serology, virus culture by con-
ventional tube method or rapid shell vial assay and anti-
gen detection. Culture is the "gold standard" but is a
relatively insensitive laboratory method and serology
results are difficult to interpret especially in immunocom-
promised patients [1-3]. pp65 antigenemia assay is used
as a test for monitoring those at higher risk of developing
CMV disease and to initiate pre-emptive therapy [4,5].
Detection of HCMV DNA in clinical specimens by nucleic
acid based amplification methods such as Polymerase
chain reaction (PCR) contributes to a rapid and early diag-
nosis [6-8]. Primer pairs for the detection of the genes
coding for the Immediate Early (IE) antigen and Late anti-
gen (LA) were initially used for the detection of HCMV
genome in urine and peripheral blood leucocyte speci-
mens [9,10]. Since then, a variety of primer pairs are being
used for routine diagnosis of HCMV infection in various
patient populations. Sequence variations in the viral
genome have been shown to affect the ability of the PCR
using different primer sets to detect HCMV DNA [11-14].
Little is known about the sequence variations in the
regions of HCMV genome under the present study viz:
morphological transforming region II (mtr II), UL 83 and
glycoprotein O (gO) gene. The PCRs for the aforemen-
tioned regions were already standardized in our labora-
tory using cultures of CMV AD-169 strain (ATCC VR-538).
pp65 antigenemia assay is a rapid, reliable and superior to
both rapid shell vial assay and conventional test tube cul-
ture in the detection of HCMV in the clinical specimens
from immunocompromised patients indicating active
HCMV disease. [15,16]. Therefore, the antigenemia assay
was considered as "gold standard" in the present study to
evaluate the efficacy of the three Polymerase chain reac-
tion tests to detect HCMV genome in the clinical speci-
mens of clinically suspected HCMV disease in
immunocompromised patients in Chennai, India.
Results
Of the total 92 specimens from 74 patients tested, the pp
65 antigenemia was present in 48 clinical specimens from
38 patients and these were considered as positive for the
"gold standard", definition for active CMV disease. The
patients in whom pp65 antigenemia was positive pre-
sented a mean of 44.7 positive cells in the antigenemia
assay (range 13 – 162 cells). HCMV was isolated from
three clinical specimens (one peripheral blood leucocyte
and two urine) from three patients, positive for pp65 anti-
genemia. Of the total 48 clinical specimens positive by the
"gold standard", when tested by PCR methods all were
positive for mtr II region, 27 for UL -83 gene and 21 for
gO gene. This increase in clinical sensitivity by the PCR for
mtr II over the UL 83 and gO PCRs were 44% and 56%
respectively. The increase in the clinical sensitivity of the
PCR for mtr II was statistically significant (P < 0.0001 by
Fisher's exact test for two proportions). However, the dif-
ference in the clinical specificity between the three PCR
tests were not statistically significant (P >0.08, by Fisher's
exact test for two proportions). A summary of the results
for the clinical specimens is presented in Table 2. All the
45 peripheral blood leucocytes obtained from the con-
trols (seropositive healthy donors) remained negative by
pp65 antigenemia assay and all the three PCR tests for
HCMV.
Discussion
Human Cytomegalovirus has long been recognized as a
major cause of life- threatening complications in immu-
nosuppressed individuals. There is perceived need for the
use of a reliable technique that allows an early detection
of the viral activation to help decide on early use of pre-
emptive therapy in those at greater risk of the disease.
Technique such as virus isolation though most specific
cannot be practiced on a regular basis due to lack of its
sensitivity and non-availability of human diploid fibrob-
lasts in this part of the world. Quantitative pp 65 antigen-
emia, used to monitor and detect CMV disease, is well
established to have a higher positive predictive value for
the disease [3]. Since antigenemia is cell based and a low
frequency event, a sufficient number of granulocytes are
necessary for a reliable result [3]. This becomes difficult in
Bone marrow transplant or other patients with severe leu-
copenia. Other difficulties include the necessity for imme-
diate processing of the specimen (within 6 hrs, stored
specimens may give erroneous results), difficulty in
processing a large number of specimens at a time and sub-
jective component in slide reading, which requires exper-
tise [3]. The drawbacks of pp65 antigenemia assay or virus
isolation may be overcome by the use of rapid, sensitive
and normalized method such as PCR for the detection of
HCMV genome in the clinical specimens, which can be
applied on a large scale of clinical specimens without any
difficulty in a standard laboratory for routine diagnosis of
HCMV infection.
Amplification of HCMV genome by PCR is a rapid and
sensitive method for detection of HCMV in clinical speci-
mens. The choice of PCR primers for HCMV genome
detection in a clinical specimen is crucial since the
genome of HCMV is reported to be highly variable [11-
14]. The primers targeting regions such as the Major
immediate early gene exon 4, regions of gene coding late
antigen, glycoprotein B (gB) and glycoprotein H (gH)
which are widely used have failed to detect the HCMV
genome in certain clinical specimens due to primer target
mismatch owing to the large sequence variations in
HCMV genome. Nucleotide substitutions and even dele-
tions of certain ORFs have been found along the genome
of HCMV [17]. Studies by Distefano et al., suggested that
PCR for gB gene was more reliable than the Major imme-Virology Journal 2006, 3:20 http://www.virologyj.com/content/3/1/20
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diate early gene exon 4 or Late antigen gene in detecting
HCMV genome in the clinical specimens from congenital
and perinatal infections in Argentina [13]. Studies by Wir-
gart et al. suggested that the DNA polymerase gene and gB
gene were more conserved and can be used for diagnosis
of HCMV infections in different patient populations [14].
PCRs for gB and gH genes of HCMV were compared in a
Brazilian study on the renal transplant recipients by
Aquino and Figueiredo where in a multiplex format of
both the genes was suggested for reliable detection of
HCMV genome [18]. PCRs for MIE gene (IE1), glycopro-
tein B (gp 58) and structural phosphoprotein (pp 150)
were compared with pp 65 antigenemia in heart and lung
transplant recipients by Barber et al. where in all the PCR
showed a high sensitivity of 100% though gp 58 was asso-
ciated more with a positive PCR signal than the other two
PCRs [19].
There are only a few reports available on the primers tar-
geting the regions of HCMV genome under the present
study [20-22]. Therefore, the efficacy of these three prim-
ers were evaluated on different clinical specimens
obtained from different high risk immunocompromised
patient populations against pp65 antigenemia assay as
gold standard. Blood from the healthy seropositive con-
trols did not yield any detectable CMV DNA by any of the
three PCRs following amplification. Thus, though the
PCRs were considered as highly sensitive methods, they
did not detect low – level latent HCMV infection present
in the healthy immunocompetent individuals in this
study.
pp65 antigenemia assay detected active CMV disease in 38
of 74 patients. The virus isolation had a low sensitivity,
positive only in three out of 12 patients with CMV disease
as evidenced by a positive antigenemia and these were
positive by PCR for all the three regions. We hypothesise
that PCRs for all the three regions may become positive
only with a high viral load.
The failure of the PCR targeting UL 83 may be due to its
lower analytical sensitivity, as it is a uniplex PCR. The PCR
for gO gene though a nested PCR, shows a lower clinical
sensitivity than the uniplex PCR for UL 83 and this may
be attributed to the strain variations in gO gene leading to
the primer target mismatch and hence loss of an amplifi-
cation signal.
Conclusion
Results of our study showed that the PCR for mtr II had
100% sensitivity, 100 % negative predictive value, 87%
positive predictive value and 84% specificity. Therefore, it
is the most suitable for routine use in Chennai region in
India.
Table 1: Distribution of 92 clinical specimens in relation to the clinical status of the 74 patients with suspected CMV infections.
Clinical Status of the Patients Total number of patients 
(n = 74)
Clinical Specimens collected 
(n= 92)
Blood only 
(n= 56)
Blood and urine 
(n = 18 × 2 : 36)
Solid organ transplantation 59 (79.7%) 43 16
Bone marrow transplantation 3 (4.0%) 3 -
HIV infected individuals 7(9.5%) 7 -
Congenital/neonates 5(6.8%) 3 2
Table 2: Results of the three PCRs for the diagnosis of suspected CMV infections in comparison to pp65 antigenemia (gold standard)a.
Diagnostic test result pp65 Positives (n = 48) pp65 Negatives (n = 44)
No. of Clinical 
specimens
SENS (%) PPV (%) FN (%) No. of Clinical 
specimens
SPEC (%) NPV (%) FP (%)
PCR for mtrII positive 48 100 87 0 7 84 100 14
PCR for mtr II negative 0 37
PCR for UL 83 positive 27 56 87 44 4 91 66 8
PCR for UL 83 negative 21 40
PCR for gO positive 21 44 91 56 2 95 61 4
PCR for gO negative 27 42
aAbbreviations: SENS, sensitivity; PPV, Positive predictive value; FN, False negative; SPEC, specificity; NPV, Negative predictive value; FP, False 
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Methods
Study design
Clinical specimens were investigated at L & T Microbiol-
ogy Research Centre, Vision Research Foundation, in
Sankara Nethralaya, Chennai, India during December
2004 to July 2005 for the possible association of CMV
infection in 74 immunocompromised patients. Clinical
specimens were investigated because of clinical suspicion
of CMV- related disease in these patients. The patients
with pp65 antigenemia positivity were defined to have
activation of CMV disease and this test was used as the
"gold standard" to evaluate the three PCRs for their clini-
cal specificity, sensitivity and predictive values [20-22].
Patients and specimens
The distribution of the clinical specimens in relation to
the clinical status of the patients from whom they were
collected is provided in Table 1. In total, 92 specimens [74
blood, 18 urine] from 74 patients were analyzed during
the course of the study. In addition blood samples from
45 healthy blood donors with no history or recent CMV
infection but seropositive for CMV were used as controls
for all the tests. Among the 74 patients, 47 were males and
27 females. The age of the patients ranged from 40 hours
after birth to 67 years. The patients clinically presented
with multiple symptoms such as fever, jaundice and leu-
copenia. Three of the renal transplant recipients had a
clinical evidences of a moderate graft rejection. CMV
retinitis was predominant in the HIV infected individuals.
Virus isolation
Virus isolation was performed on 12 clinical specimens
(peripheral blood leucocytes and urine specimens of six
patients) using rapid shell vial technique. Human Tenon's
capsule fibroblasts grown on cover slips were inoculated
with the clinical specimens. For inoculation purposes,
100 µl of peripheral blood leukocyte suspension of blood
specimens and 100 µl of decontaminated centrifuged
deposits of the urine specimens were used. The cover slips
were stained at 48 h with mouse monoclonal antibody
(DAKO, A/S, Denmark) raised against the early antigen of
HCMV and rabbit anti-mouse fluorescein thiocyanate
conjugate (DAKO, A/S, Denmark). One or more positive
fluorescent nuclei indicated positive result [20].
pp65 antigenemia assay
pp65 antigenemia for CMV was carried out on 5 ml of
EDTA anticoagulated blood within six hours of receipt of
the specimen as described previously with few modifica-
tions [23]. In brief, Cytospin smear made with the 2 × 105
leucocytes obtained from EDTA anticoagulated blood
after dextran sedimentation and erythrolysis using 0.8%
ammonium chloride was fixed in methanol for 10 min-
utes. The cells were permeabilized using 0.5% Non-idet
P40. The smears were stained with mouse monoclonal
antibody (DAKO, A/S, Denmark) raised against the pp65
antigen of HCMV and rabbit anti-mouse fluorescein thio-
cyanate conjugate (DAKO, A/S, Denmark). 0.5 % Evan's
blue (Himedia, India), was used as a counter stain. The
smears were examined under fluorescent microscope
(Optiphot, Nikon, Japan). A positive assay result was
defined by the presence of at least 1 positively stained leu-
kocyte on the slide, and the result was expressed as the
number of CMV pp65-positive cells per 2 × 105 leuko-
cytes.
PCR amplification of the three target regions
The extraction of the DNA was performed using two com-
mercially available DNA extraction columns strictly
adhering to the manufacturer's instruction. For blood
specimens, 100 µl of the buffy coat was extracted using
QIAamp DNA mini Kit (QIAGEN, Germany). For urine
and culture harvests Biogene DNA extraction kit, (BIO-
GENE Reagents Inc, CA, USA) was used. The PCR for
detection of mtrII region was performed as described [20].
The nested primers of mtr II, CMTR 1-5'-CTG TCG GTG
ATG GTC TCT TC-3' and CMTR 2-5'-CCC GAC ACG CGG
AAA AGA AA-3' for the first round and CMTR3 5' TCT
CTG GTC CTG ATC GTC TT-3' and CMTR4-5'-GTG ACC
TAC CAA CGT AGG TT-3' for the second round generated
234 bp and 168 bp products respectively The PCR for
detection of gO gene was performed as previously
described [21]. The nested primers of gO, gO 1-5'-CAG
CTT CGA AAA CCG GCC AAA TAC G-3' and gO 2-5'-AAT
ATA CTT GGG GAC GCG AAA TAG A-3' for the first round
generated a 375 bp and gO3-5'-GCT TCG AAA ACC GGC
CAA ATA CG-3' and gO4-5'-ATA CTT GGG GAC GCG
AAA TAG A-3' for the second round generated a 370 bp
product. The primers of the UL 83 PCR, which were orig-
inally designed for application in 5' nuclease, assay and
were adapted for standard uniplex PCR by us [22]. The
uniplex primers of UL-83, UL83 1-5'-GGG ACA CAA CAC
CGT AAA GC-3' and UL83 2-5'-GTC AGC GTT CGT GTT
TCC CA-3' generated a 283 bp product. Analysis of the
PCR products (10 µl) was undertaken by electrophoretic
separation on an ethidium bromide-stained 2% agarose
gel. The analytical sensitivity of the PCRs for mtr II, UL 83
and gO gene were determined by application of the indi-
vidual PCRs on log dilutions of AD169 DNA and was
found to be 1 fg, 50 fg and 500 fg of HCMV DNA respec-
tively.
Statistical analysis
Diagnostic data from clinical specimens of 74 patients
with suspected CMV infections were used for the determi-
nation of the clinical sensitivity, specificity, positive pre-
dictive values and negative predictive values of the three
different PCR results using pp65 antigenemia and/or cul-
ture results as the "gold standard"[24]. The difference in
the clinical sensitivity and the specificity of the three dif-Publish with BioMed Central    and   every 
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ferent PCRs were statistically analyzed by Fisher's exact
test for two proportions.
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